Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below 50 Day Moving Average - Time to Sell?

Key Points

• Technical signal: Fennec's shares slipped below the 50‑day moving average to C$10.18 (50‑day = C$10.80) and were down about 5% on very light volume, indicating short‑term bearish momentum.
• Analyst outlook: B. Riley Financial upgraded the stock to a "strong‑buy" and the consensus rating on MarketBeat is currently "Strong Buy," providing a contrasting bullish analyst view.
• Insider activity: Southpoint Capital Advisors sold 1,000,000 shares (reducing its stake by 26.7%) at an average C$10.35, while a director purchased 15,598 shares at C$3.37; company insiders now own 16.20% of the stock.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$10.80 and traded as low as C$10.18. Fennec Pharmaceuticals shares last traded at C$10.18, with a volume of 101 shares.

Wall Street Analyst Weigh In

Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Strong Buy".

Fennec Pharmaceuticals Stock Down 5.0%

The stock has a market capitalization of C$347.68 million, a price-to-earnings ratio of -39.15 and a beta of 3.01. The firm has a 50 day simple moving average of C$10.80 and a 200-day simple moving average of C$11.33. The company has a debt-to-equity ratio of -403.07, a current ratio of 4.69 and a quick ratio of 10.17.

Insider Activity

In other Fennec Pharmaceuticals news, insider Southpoint Capital Advisors Lp sold 1,000,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of C$10.35, for a total value of C$10,350,000.00. Following the transaction, the insider directly owned 2,744,741 shares in the company, valued at C$28,408,069.35. The trade was a 26.70% decrease in their ownership of the stock. Also, Director Rostislav Christov Raykov purchased 15,598 shares of Fennec Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was purchased at an average price of C$3.37 per share, for a total transaction of C$52,565.26. Following the completion of the transaction, the director owned 2,719,643 shares of the company's stock, valued at approximately C$9,165,196.91. This represents a 0.58% increase in their ownership of the stock. Company insiders own 16.20% of the company's stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.